Inovio Pharmaceuticals (Inovio Pharmaceuticals) Interest Expense : $-1.22 Mil (TTM As of Dec. 2023)

View and export this data going back to 1998. Start your Free Trial

What is Inovio Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Inovio Pharmaceuticals's interest expense for the three months ended in Dec. 2023 was $ -0.28 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.22 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Inovio Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $ -27.39 Mil. Inovio Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $ -0.28 Mil. Inovio Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Inovio Pharmaceuticals Interest Expense Historical Data

The historical data trend for Inovio Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inovio Pharmaceuticals Interest Expense Chart

Inovio Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-7.95

-8.70

-1.94

-1.25

-1.22

Inovio Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.31	-0.31	-0.31	-0.31	-0.28

Inovio Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.22 Mil.

Inovio Pharmaceuticals (NAS:INO) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Inovio Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $-0.28 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-27.39 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $11.03 Mil.

Inovio Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Inovio Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Inovio Pharmaceuticals (Inovio Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (NAS:INO) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

INO:Mexico GBMB:Germany GBMB:Germany

Address

660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462

Website

https://www.inovio.com

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Executives

Lota S. Zoth	director	334 CR 692, BUFFALO GAP TX 79508
David B. Weiner	director	717 BEACOM LANE, MERION STATION PA 19066-1603
Simon X Benito	director	967 LAWRENCE AVE, WESTFIELD NJ 07090
Michael John Sumner	officer: Chief Medical Officer	660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Laurent Humeau	officer: Chief Scientific Officer	C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jacqueline Elizabeth Shea	officer: Chief Operating Officer	C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Peter Kies	officer: CFO
Roger D Dansey	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Jong Joseph Kim	director, officer: Chief Executive Officer	660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jay Shepard	director	15977 GRANDVIEW AVENUE, MONTE SERENO CA 95030
Ann Calby Miller	director	C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Wendy L Yarno	director
Morton Collins	director
George Bickerstaff	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Niranjan Sardesai	officer: Chief Operating Officer	VGX PHARMACEUTICALS, INC., 450 SENTRY PARKWAY, BLUE BELL PA 19422